CompletedPhase 1NCT00110552

Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients

Studying Early-onset autosomal dominant Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Oregon Health and Science University
Principal Investigator
Barry Oken, MD
Oregon Health and Science University
Intervention
Salvia officinalis (sage)(drug)
Enrollment
111 target
Eligibility
50-90 years · All sexes
Timeline
20052014

Study locations (1)

Collaborators

National Center for Complementary and Integrative Health (NCCIH)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00110552 on ClinicalTrials.gov

Other trials for Early-onset autosomal dominant Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for Early-onset autosomal dominant Alzheimer disease

← Back to all trials